Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004122 · ClinicalTrials.gov registry record · Phase 2
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004122: Completed Phase 2 study, sponsored by Roswell Park Cancer Institute.
NCT00004122 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004122, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. Interferon alfa may interfere with the growth of cancer cells. Combining these therapies may be an effective treatment for bladder cancer. PURPOSE: Phase II trial to study the effectiveness of BCG plus interferon alfa 2b in treating patients who have bladder cancer.
Interventions
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL BCG vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Phase | Phase 2 |
What the finished NCT00004122 record still lists
NCT00004122 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which recombinant interferon alfa is the first listed.
NCT00004122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004122 about?
NCT00004122 is a clinical study titled "BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer". RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. Interferon alfa may interfere with the growth of cancer cells. Combining these therapies may be an effective treatment for bladder cancer. PURPOSE: Phase II trial to stu...
What is the current status of trial NCT00004122?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-07.
What interventions are being tested in trial NCT00004122?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), BCG vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004122?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia